2023 , MND, K9 Cancer Commercial Deal , Covid , Human Cancer, OHD, page-92

Patent should be granted now for the Covid vs MPL Treatment , This would be a significant Catalyst and would certainly interest Big Pharma especially Pfizer.... and Roger has a solid relationship with Pfizer reinforced this year with the sale of RAP for $180m to Pfizer...

PharmAust files patent for monepantel in viral diseases
● PharmAust files PCT (Patent Cooperative Treaty) patent for monepantel and aminoacetonitrile derivatives as antiviral agents
● Earliest priority date claimed is 11 May 2020
● Publication date approximately November 2021

22 July 2021 – Perth, Australia: PharmAust Limited (ASX: PAA), a clinical-stage biotechnology
company, is pleased to provide an update on its patent applications for the use of monepantel in viral
diseases.
PharmAust has filed a PCT application which, amongst other aspects, is directed towards the use of
monepantel and aminoacetonitrile derivatives as antiviral agents and claims an earliest priority date of
11 May 2020.
It is expected that the application will be open for public inspection (OPI) around November 2021.
This announcement is authorised by the Board.